{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T22:30:36Z","timestamp":1774737036903,"version":"3.50.1"},"reference-count":47,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T00:00:00Z","timestamp":1732665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nucl. Med."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>The aims of this study were to evaluate and compare fibroblast activation protein (FAP) expression and localization in surgically resected cholangiocarcinoma (CCA), primary and metastatic hepatocellular carcinoma (HCC), hepatocellular adenoma (HCA), and focal nodular hyperplasia (FNH), and to identify any association between CCA clinical or pathologic features and FAP expression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and methods<\/jats:title><jats:p>FAP immunostaining from surgically resected CCA (<jats:italic>N<\/jats:italic>\u2009=\u200958), primary intrahepatic and extrahepatic metastatic HCC (<jats:italic>N<\/jats:italic>\u2009=\u2009148), HCA (N26), and FNH (<jats:italic>N<\/jats:italic>\u2009=\u200919) was scored (negative, weak positive, moderate positive or strong positive) from tissue microarrays. FAP expression was compared between groups. CCA FAP expression was compared to clinical and tumor pathology features.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Moderate-strong FAP expression in the tumor stroma was present in 93.1% of CCA, 60.7% of extrahepatic metastatic HCC, 29.6% of primary HCC, 21.1% of FNH, and 11.6% of HCA. Moderate-strong FAP expression in tumor stroma was significantly more prevalent in CCA than HCC (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), metastatic HCC (<jats:italic>p<\/jats:italic>\u2009=\u20090.005), HCA (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001) and FNH (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). FAP was expressed in the stroma of all but one CCA (1.7%), and FAP expression in CCA tumor stroma was not associated with any clinical or tumor pathology features (<jats:italic>p<\/jats:italic>\u2009&amp;gt;\u20090.05, all).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>FAP is expressed in the stroma of a high proportion (93%) of primary CCA independent of patient clinical or tumor pathology features. As such, these data provide the tissue basis for systematically evaluating FAP as a theranostic target across a broad range of CCA subtypes.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fnume.2024.1480471","type":"journal-article","created":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T04:22:36Z","timestamp":1732681356000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunohistochemical basis for FAP as a candidate theranostic target across a broad range of cholangiocarcinoma subtypes"],"prefix":"10.3389","volume":"4","author":[{"given":"Laura C.","family":"Jorgenson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Torbenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thorvardur R.","family":"Halfdanarson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lionel A.","family":"Kankeu Fonkoua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nguyen H.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis R.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rory L.","family":"Smoot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ajit H.","family":"Goenka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott M.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1055\/s-2007-1007302","article-title":"Recent advances in the management of cholangiocarcinomas","volume":"14","author":"Vauthey","year":"1994","journal-title":"Semin Liver Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1053\/jhep.2001.25087","article-title":"Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States","volume":"33","author":"Patel","year":"2001","journal-title":"Hepatology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.5009\/gnl.2009.3.4.298","article-title":"Natural history and prognostic factors of advanced cholangiocarcinoma without surgery, chemotherapy, or radiotherapy: a large-scale observational study","volume":"3","author":"Park","year":"2009","journal-title":"Gut Liver"},{"key":"B6","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann Surg"},{"key":"B7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/00000658-199610000-00005","article-title":"Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors","volume":"224","author":"Nakeeb","year":"1996","journal-title":"Ann Surg"},{"key":"B8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/hep.31410","article-title":"The tumor microenvironment in cholangiocarcinoma progression","author":"Fabris","year":"2021","journal-title":"Hepatology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fonc.2017.00003","article-title":"Characterization of the tumor microenvironment and tumor-stroma interaction by non-invasive preclinical imaging","volume":"7","author":"Ramamonjisoa","year":"2017","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1093\/jnci\/djs336","article-title":"Targeting carcinoma-associated fibroblasts within the tumor stroma with a fibroblast activation protein-activated prodrug","volume":"104","author":"Brennen","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1073\/pnas.0909797107","article-title":"Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers","volume":"107","author":"Saadi","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B12","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00259-021-05488-9","article-title":"FAP Imaging in rare cancer entities-first clinical experience in a broad spectrum of malignancies","volume":"49","author":"Dendl","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"(68)Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J Nucl Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1097\/MOG.0b013e32834405c3","article-title":"Cancer-associated fibroblasts in intrahepatic cholangiocarcinoma","volume":"27","author":"Sirica","year":"2011","journal-title":"Curr Opin Gastroenterol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1007\/s00259-020-05070-9","article-title":"Comparison of PET imaging of activated fibroblasts and (18)F-FDG for diagnosis of primary hepatic tumours: a prospective pilot study","volume":"48","author":"Shi","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B16","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s11307-022-01732-2","article-title":"Comparisons of quantitative parameters of Ga-68-labelled fibroblast activating protein inhibitor (FAPI) PET\/CT and [(18)F]F-FDG PET\/CT in patients with liver malignancies","volume":"24","author":"Siripongsatian","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J Nucl Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","article-title":"A tumor-imaging method targeting cancer-associated fibroblasts","volume":"59","author":"Loktev","year":"2018","journal-title":"J Nucl Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.2967\/jnumed.118.214361","article-title":"Fibroblast-Activating protein: targeting the roots of the tumor microenvironment","volume":"59","author":"Siveke","year":"2018","journal-title":"J Nucl Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1002\/hep4.1861","article-title":"PSMA As a theranostic target in hepatocellular carcinoma: immunohistochemistry and (68) Ga-PSMA-11 PET using cyclotron-produced (68) Ga","volume":"6","author":"Thompson","year":"2022","journal-title":"Hepatol Commun"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.2967\/jnumed.124.268351","article-title":"Correlation of FAPI PET uptake with immunohistochemistry in explanted lungs from patients with advanced interstitial lung disease","volume":"65","author":"Hotta","year":"2024","journal-title":"J Nucl Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1007\/s00259-023-06246-9","article-title":"FAP Expression in alpha cells of langherhans insulae-implications for FAPI radiopharmaceuticals\u2019 use","volume":"50","author":"Kirienko","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B23","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"B24","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.1097\/RLU.0000000000004652","article-title":"68 Ga-FAPI PET\/CT provides a clear picture of a klatskin tumor that 18 F-FDG PET\/CT missed","volume":"48","author":"Al-Ibraheem","year":"2023","journal-title":"Clin Nucl Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1007\/s00259-020-05095-0","article-title":"Imaging fibroblast activation protein in liver cancer: a single-center post hoc retrospective analysis to compare [(68)Ga]Ga-FAPI-04 PET\/CT versus MRI and [(18)F]-FDG PET\/CT","volume":"48","author":"Guo","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B27","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1007\/s00259-023-06137-z","article-title":"Clinical prospective study of Gallium 68 ((68)Ga)-labeled fibroblast-activation protein inhibitor PET\/CT in the diagnosis of biliary tract carcinoma","volume":"50","author":"Jinghua","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B28","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.cpet.2023.02.011","article-title":"The diagnostic value of fibroblast activation protein imaging in hepatocellular carcinoma and cholangiocellular carcinoma","volume":"18","author":"Novruzov","year":"2023","journal-title":"PET Clin"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.2967\/jnumed.122.265215","article-title":"Superior tumor detection for (68)Ga-FAPI-46 versus (18)F-FDG PET\/CT and conventional CT in patients with cholangiocarcinoma","volume":"64","author":"Pabst","year":"2023","journal-title":"J Nucl Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e281","DOI":"10.1097\/RLU.0000000000004641","article-title":"Role of 68Ga-FAPI PET\/CT in assessing hepatobiliary malignancies: a prospective pilot study","volume":"48","author":"Rajaraman","year":"2023","journal-title":"Clin Nucl Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s13139-021-00712-8","article-title":"(68)Ga-FAPI-46 PET\/MR detects recurrent cholangiocarcinoma and intraductal papillary mucinous neoplasm in a patient showing increasing CEA with negative (18)F-FDG PET\/CT and conventional CT","volume":"55","author":"Siripongsatian","year":"2021","journal-title":"Nucl Med Mol Imaging"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1097\/RLU.0000000000004965","article-title":"Elevated 18 F-AIF-FAPI-04 uptake in hepatic hemangioma","volume":"49","author":"Sun","year":"2024","journal-title":"Clin Nucl Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.3390\/diagnostics12081958","article-title":"FAPI PET versus FDG PET, CT or MRI for staging pancreatic-, gastric- and cholangiocarcinoma: systematic review and head-to-head comparisons of diagnostic performances","volume":"12","author":"Veldhuijzen van Zanten","year":"2022","journal-title":"Diagnostics"},{"key":"B34","doi-asserted-by":"publisher","first-page":"S909-S","DOI":"10.1016\/S0016-5085(11)63773-6","article-title":"Myofibroblast-Derived PDGF-BB promotes hedgehog signaling-dependent resistance to TRAIL cytotoxicity in cholangiocarcinoma cells","volume":"140","author":"Fingas","year":"2011","journal-title":"Gastroenterology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1016\/j.neo.2019.10.005","article-title":"Fibroblastic FAP promotes intrahepatic cholangiocarcinoma growth via MDSCs recruitment","volume":"21","author":"Lin","year":"2019","journal-title":"Neoplasia"},{"key":"B36","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1038\/s41388-018-0275-3","article-title":"Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics","volume":"37","author":"Pur\u00e9","year":"2018","journal-title":"Oncogene"},{"key":"B37","doi-asserted-by":"publisher","first-page":"616a-a","DOI":"10.1111\/j.1872-034X.2012.01026.x","article-title":"Organotypic cell culture modeling of desmoplastic cholangiocarcinoma progression","volume":"56","author":"Sirica","year":"2012","journal-title":"Hepatology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1002\/hep.26762","article-title":"Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting","volume":"59","author":"Sirica","year":"2014","journal-title":"Hepatology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00259-020-04940-6","article-title":"Usefulness of [(68)Ga]Ga-DOTA-FAPI-04 PET\/CT in patients presenting with inconclusive [(18)F]FDG PET\/CT findings","volume":"48","author":"Chen","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B40","doi-asserted-by":"publisher","first-page":"e0294564","DOI":"10.1371\/journal.pone.0294564","article-title":"Gallium-68-labeled fibroblast activation protein inhibitor-46 PET in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma: a phase 2, multicenter, single arm, open label non-randomized study protocol","volume":"18","author":"Karbhari","year":"2023","journal-title":"PLoS One"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of fibroblast activation protein-targeted radiotracers with improved tumor retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J Nucl Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.2967\/jnumed.119.239731","article-title":"Design and development of (99m)Tc-Labeled FAPI tracers for SPECT imaging and (188)Re therapy","volume":"61","author":"Lindner","year":"2020","journal-title":"J Nucl Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jhep.2016.06.024","article-title":"Functional imaging in liver tumours","volume":"65","author":"Ronot","year":"2016","journal-title":"J Hepatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.gassur.2003.10.003","article-title":"Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma","volume":"8","author":"Anderson","year":"2004","journal-title":"J Gastrointest Surg"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1007\/s00259-003-1297-8","article-title":"Usefulness of 18F-FDG PET in intrahepatic cholangiocarcinoma","volume":"30","author":"Kim","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1142690","DOI":"10.3389\/fimmu.2023.1142690","article-title":"Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma","volume":"14","author":"Du","year":"2023","journal-title":"Front Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","article-title":"Immunology and immunotherapy of cholangiocarcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Frontiers in Nuclear Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnume.2024.1480471\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T04:22:42Z","timestamp":1732681362000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnume.2024.1480471\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":47,"alternative-id":["10.3389\/fnume.2024.1480471"],"URL":"https:\/\/doi.org\/10.3389\/fnume.2024.1480471","relation":{},"ISSN":["2673-8880"],"issn-type":[{"value":"2673-8880","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]},"article-number":"1480471"}}